醫藥品的授權合約交易 (2019～2024年)

本報告提供全球醫藥品的授權合約交易的締結狀況相關分析，彙整整體交易數量的轉變和預測 (2019～2024年)，近幾年的代表性交易案例，主要企業的交易締結動向，各技術·各治療領域達成交易的動向等資訊，為您概述為以下內容。

目錄

摘要整理

第1章 簡介

第2章 授權合約交易趨勢

• 簡介
• 授權合約交易定義
• 授權合約交易趨勢 (2019年以後)
  • 授權合約交易趨勢:各年度 (2019～2024年)
  • 授權合約交易趨勢:各開發階段 (2019～2024年)
  • 授權合約交易趨勢:各產業領域 (2019～2024年)
  • 授權合約交易趨勢:各治療領域 (2019～2024年)
  • 授權合約交易趨勢:各技術種類 (2019～2024年)
  • 授權合約交易趨勢:最活躍的企業的情況 (2019～2024年)
• 簽訂授權合約的聯盟交易的理由
• 授權合約交易的未來性

第3章 授權合約交易結構:概要

• 簡介
• 授權合約結構

第4章 授權合約的主要的交易

• 簡介
• 授權合約前幾名的交易 (以金額為準)

第5章 授權合約交易:最活躍的交易締結25企業

• 簡介
• 授權合約交易:最活躍的交易締結25企業

第6章 授權合約交易:契約的明細

• 簡介
• 授權合約契約 (2019～2024年)
• 交易明細
• 交易明細:授權合約的交易締結，企業名 (A～Z)
• 交易明細:授權合約的交易締結，各治療領域
• 交易明細:授權合約的交易締結，各技術種類

關於Wildwood Ventures

Licensing Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter licensing deals.

Fully revised and updated, the report provides details of licensing deals from 2019 to 2024.

The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals.

Chapter 4 provides a review of the leading licensing deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active licensing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of licensing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the licensing deal.

The deal directory includes a comprehensive listing of all licensing deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2019.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.

Key benefits

Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Licensing Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading biopharma companies worldwide.

Licensing Deals in Pharmaceuticals includes:

• Trends in licensing dealmaking in the biopharma industry
• Overview of licensing deal structure
• Directory of licensing deal records covering pharmaceutical and biotechnology
• The leading licensing deals by value
• Most active licensing dealmakers
• The leading licensing partnering resources

In Licensing Deals in Pharmaceuticals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Licensing Deals in Pharmaceuticals provides comprehensive access to available records for licensing deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2019
  • 2.3.1. Licensing dealmaking by year, 2019-2024
  • 2.3.2. Licensing dealmaking by phase of development, 2019-2024
  • 2.3.3. Licensing dealmaking by industry sector, 2019-2024
  • 2.3.4. Licensing dealmaking by therapy area, 2019-2024
  • 2.3.5. Licensing dealmaking by technology type, 2019-2024
  • 2.3.6. Licensing dealmaking by most active company, 2019-2024
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts 2019-2024
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements, 2019-2024
• Figure 3: Licensing deals signed at each phase of development, 2019-2024
• Figure 4: Licensing deals by industry sector, 2019-2024
• Figure 5: Licensing deals by therapy area, 2019-2024
• Figure 6: Licensing deals by technology type, 2019-2024
• Figure 7: Top 25 most active licensing dealmakers, 2019-2024
• Figure 8: Top licensing deals by value, 2019-2024
• Figure 9: Most active licensing dealmakers, 2019-2024